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SINTESIS, PENCIRIAN DAN KAJIAN IN SILIKO BAGI TERBITAN 
PIPERIDON: KAJIAN PERENCAT DENGGI PROTEASE TERHADAP 
SEBATIAN TERPILIH  
ABSTRAK 
 
 Komponen yang aktif daripada segi biologi 26(a-j) and 27(a-j) yang 
mempunyai terbitan piperidone telah disintesis dengan mengabungkan terbitan 
asetofenon dengan pelbagai terbitan 3,5-bis(arylidenepiperidin)-4-on dengan 
kehadiran K2CO3 sebagai pemangkin dibawah tindak balas penggantian nukleofilik. 
Sebatian yang disintesis diperolehi dengan purata hasil 58.00-89.90 % dan dicirikan 
secara menyeluruh dengan IR, 
1
H NMR, 
13
C NMR, DEPT dan analisis unsur.  
Struktur sebatian selanjutnya dikenal pasti dengan teknik spektroskopi 2D NMR 
(COSY, HSQC dan HMBC) dan juga kristalografi sinar X. Sebatian yang disintesis 
disaring secara maya menggunakan struktur model homologi Wilchapong melalui 
kajian pendokan molekul dengan menggunakan AutoDock 4.2.5 untuk mendedahkan 
mekanisme interaksi ikatan dan orientasi sebatian terhadap protease DENV2 NS2B-
NS3. Sebatian 26h dan 27h diperhatikan mempunyai ikatan tertinggi terhadap 
protease disamping mempunyai interaksi dengan asid amino penting iaitu His51 dan 
Ser135 dalam kawasan triad pemangkin masing-masing dengan nilai -11.06 kcal/mol 
dan -11.36 kcal/mol. Sebatian selebihnya mempunyai tenaga ikatan yang baik 
berbanding dengan struktur hablur model homologi. Sebatian 26h dan 27h yang 
terpilih melalui ujian aktiviti perencat terhadap enzim protease NS2B-NS3 denggi-2 
menggunakan substrat peptida Boc-Gly-Arg-Arg-MCA. Kedua-dua sebatian yang 
mempunyai p-NO2 pada gelang aromatik menunjukkan aktiviti perencatan yang 
xix 
 
tinggi terhadap protease dengan nilai IC50 masing-masing ialah 15.13 µM ±1.05 dan 
16.14 µM ±1.23. 
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SYNTHESIS, CHARACTERIZATION AND IN SILICO STUDIES OF 
PIPERIDONE DERIVATIVES: DENGUE PROTEASE INHIBITORY 
STUDIES ON SELECTED COMPOUNDS 
ABSTRACT 
 
 New biologically active compounds 26(a-j) and 27(a-j) comprising 
piperidone derivatives were synthesized by incorporating acetophenone derivatives 
with varies of 3,5-bis(arylidenepiperidine)-4-one derivatives in the presence of 
K2CO3 as catalyst under nucleophilic substitution reaction. The synthesized 
compounds were obtained in the range of 58.0-89.9 % yields and were fully 
characterized by IR, 
1
H NMR, 
13
C NMR, DEPT and elemental analysis. The 
structures of some compounds were further confirmed by 2D NMR (COSY, HSQC 
and HMBC) spectroscopic techniques as well as X-ray crystallography. The 
synthesized compounds were virtually screened using Wilchapong homology model 
structure through molecular docking study by AutoDock 4.2.5 to disclose the binding 
interaction mechanism and orientation of the compounds towards DENV2 NS2B-
NS3 protease. Compounds 26h and 27h were observed to have the highest binding 
affinity towards the protease while having interaction with the essential amino acid 
residues, His51 and Ser135 in the catalytic triad with -11.06 kcal/mol and -11.36 
kcal/mol, respectively. The rest of the compounds exhibit good energy binding 
compared to the crystal structure of the model. The selected compounds, 26h and 
27h then underwent inhibition activity assays toward DENV2 NS2B-NS3 protease 
by using fluorogenic substrate Boc-Gly-Arg-Arg-MCA. Both compounds which 
bearing p-NO2 at the aromatic ring showed high inhibition activity against the 
protease with IC50 value of 15.13 µM ±1.05 and 16.14 µM ±1.23,  respectively. 
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CHAPTER 1 
INTRODUCTION 
 
 
The synthesis and chemistry of heterocyclic compounds have been 
recognized as an important branch of organic chemistry for years due to the 
attractiveness of their structural diversity and remarkable ability to serve as 
active pharmacophores and biomimetics. Heterocyclic compounds are the 
rings that possess at least one different atom other than carbon atom, such as 
oxygen, nitrogen or sulfur (Figure 1.1).   
 
Figure 1.1: Heterocyclic compounds: (i) piperidine, (ii) oxane, (iii) thiane, 
(iv) pyridine and (v) thiopyran. 
The potential applications of the heterocyclic compounds have been studied, 
these including in many fields, their utility in fundamental and theoretical 
studies and the possibility for the preparation of virtually unlimited number of 
novel heterocycles with diverse properties lead to a multitude of studies on 
the synthesis of such compounds. Nitrogen heterocycles and heterocyclic ring 
system having piperidin-4-one nucleus have received a great deal of attention 
in the literature and present years due to their role as active pharmacophores 
of historical significance. 
 Piperidone is a family of organic chemicals characterized by a 6-membered 
ring, one carbon substituted with nitrogen and a double-bonded oxygen atom. 
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Piperidones are named by the location of the nitrogen or amine group and the 
carbonyl group (ketone) on the ring. It is used in pharmaceutical companies 
and chemical manufacturers as starting material having anti-microbial 
activity (Soundarrajan, Saraswathi, and Asiyaparvin, 2011). Compounds 
having piperidone are associated with diverse pharmacological properties 
such as anti-cancer,
 
anti-microbial,
 
anti-convulsant, anti-viral,
 
anti-HlV,
 
anti-
fungal and anti-mycobacterial (Nagender et al., 2014; Reddy et al., 2013). 
Previous studies reported that there are peptide that can contribute to the 
dengue virus inhibitory , from the literature, this is not a stable peptide, on 
this note, newly piperidone derivatives compounds were synthesized with an 
aim to obtain compounds that could provide an inhibitory activity towards 
current fatal disease, dengue virus. Currently there is no vaccine or effective 
anti-viral therapy available in market for the prevention or treatment of the 
dengue fever. 
Dengue is a disease caused by the infection of the dengue virus and it has 
become a worldwide health issues and it cases have been reported increasing 
yearly (Schwartz et al., 2015). According to the World Health Organization 
(WHO), it is estimated that 3900 million people, in 128 countries, are at risk 
of infection with dengue viruses (WHO 2015). Dengue virus (DENV) is 
belongs to Flavivirade family which is transmitted to human by the bites of 
infected female mosquito namely Aedes aegypti and Aedes albopictus. There 
are five types of dengue virus (DENV): DENV-1, DENV-2, DENV-3, 
DENV-4 and DENV-5 (Mustafa et al., 2015), which each of them can cause 
dengue disease and among them, DENV type 2 is being the most prevalent 
virus in Malaysia (Liu et al., 2014). DENV can cause severe epidemic disease 
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ranging from the mild dengue fever (DF) to the life-threatening dengue 
hemorrhagic fever (DHF) and dengue shock syndrome (DSS) (Amorim et al., 
2014). 
DENV contains an approximately 11 kb positive-strand RNA genome that is 
transcribed as a single polyprotein which consists of three structural proteins, 
the capsid (C), precursor/mature membrane protein (prM/M) and the 
envelope (E) form the virion; the seven non structural proteins (NS1, NS2A, 
NS2B, NS3, NS4, NS4B and NS5) (Zhou et al., 2013). In the search for new 
drugs against this infection, the NS2B-NS3 protease of the dengue virus was 
investigated as molecular target. NS2B is a cofactor of the NS3 serine 
protease, which is crucial in the virus replication process in mammalian host 
cell (Sousa et al., 2015). NS2B-NS3 protease is a serine protease, which 
utilizes a combination of mechanism that is common to enzyme catalysis. It 
plays an important role in the viral replication as it is required for processing 
of the polyprotein prior to the assembly of the viral replicase complex 
(Tomlinson et al., 2011; Lai et al.,  2013; Liu et al., 2014) . Three conserved 
amino acid residues namely serine 135 (Ser135), histidine 51 (His51) and 
aspartic 75 (Asp75) formed the catalytic triad, the active site of NS2B-NS3 
protease (Idrees and Ashfaq, 2014). Hence, NS2B-NS3 protease is a potential 
target for the development of therapeutics against the dengue virus (Yildiz et 
al., 2013). Bioactivities interactions of the synthesized compounds towards 
DENV2 NS2B-NS3 protease can be predicted by docking studies.  
Computational docking plays an important role in the discovery of potential 
ligands that can fit at the binding site of a target biomacromolecule (Kitchen 
et al., 2004). Molecular docking process involves two basic steps: prediction 
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of the ligand conformation include its position and orientation within the 
active sites and assessment of the binding affinity (Novikov and Chilov, 
2009). The conformations of the ligand in the active site of the protease are 
ranked based on their scoring function or free energy of binding (FEB) which 
is an important criteria in the virtual screening and lead optimization of 
ligands for drug discovery. The free energy of binding, ∆G can be calculated 
based on equation as follows:  
∆G (      
            
   )    (      
            
   )   (      
            
    ∆     ) 
 
Where P refers to the protein, L refers to the ligand, V are the pair-wise 
evaluations and        denotes the loss of conformational entropy upon 
binding (Huey et al., 2007). 
AutoDock is one of the popular molecular docking softwares that can be used 
to predict the interaction between ligands and the biomacromolecular targets. 
AutoDock combines two methods: rapid grid-based energy evaluation and 
efficient search of the torsional freedom to achieve minimum interaction 
energy between the ligand and the target protein by exploring all available 
degree of freedom for the system. In addition, it is capable to find the suitable 
inhibitor in a short time (Morris and Huey, 2009). The combination of 
molecular modeling and bioassays studies become a useful approach for 
further drug development. In this study, in silico study has been performed as 
a proof of concept with the main aim to have correlation with the in vitro 
anti-dengue activity result.  
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Problem statement 
 
Currently, Dengue virus (DENV) is an important human arthropod-borne 
virus with a major impact on public health. Despite the enormous disease 
burden and health care's core associated with DENV infections, there is 
currently no licensed vaccines or specific treatment available. Hence, there is 
an urgent need for the researchers to search and develop the vaccines and 
anti-dengue drugs for the treatment of dengue. There have been many 
discoveries of potential anti-dengue synthetic compounds using many 
approaches such as in silico screening from compounds libraries, high 
throughput in vitro screening and structure-based drug design. From the 
literature review, peptide can contribute to the virus inhibitory, but it is not a 
stable structure. In the present study, new piperidone and its potential 
derivatives were synthesized due to their biological activities reported in 
many research studies, and the selected compounds are predicted for their 
molecular interaction studies towards DENV-2 NS2B-NS3 protease active 
site. The selected potentials compounds were further analyzed and evaluated 
for enzyme inhibitory activities in the search for the new DENV2 NS2B-NS3 
protease inhibitors. 
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Objectives 
 
The aims of the present study are as follow: 
1. To synthesize new piperidone derivatives (20 compounds). 
2. To purify, characterize and elucidate the structures of synthesized 
compounds using NMR spectroscopy (1D-2D NMR), FT-IR and 
elemental analysis. 
3. To investigate the binding interaction of the most active inhibitors 
inside the active site of DENV2 NS2B-NS3 protease by molecular 
docking analysis. 
4. To evaluate the anti-dengue activities of the selected synthesized 
compounds against DENV2 NS2B-NS3 protease. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Previous studies on piperidone 
 
Piperidone and its derivatives were found to show quite diverse biological activities 
such as anti-viral and anti-microbial (Reddy et al., 2013). There is special interest in 
studying the biological role of the nitrogen and the substituents in 4-piperidone series 
such as 3,5-bis(benzylidene)-4-piperidone, which showed good biological activities 
(Dimmock et al., 2001). In the research, a series of 3,5-bis(benzylidene)-4-
piperidone (1) and related N-acryloyl analogues (2) were prepared as the candidates 
of cytotoxic agents and  were studied against murine P388 and L1210 neoplasm that 
have been reported to be predictors of clinically useful anti-cancer drugs (Suffnes et 
al., 1979). The results discovered that, the average IC50 for both analogues 1 and 2 
were 44.0 and 1.77 µM, respectively, revealing 25 fold increases in cytotoxicity for 
analogue 2 that afford the theory of cytotoxicity mentioned in (Dimmock et al., 
1993). 
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Compound 1 were used as lead molecule for the development candidates for anti-
mycobacterial agents that showed excellent potential towards M.tuberculosis 
(Umarshankar et al., 2008), it was also reported to completely inhibited the 
microorganism growth at concentration of 6.25 µg/mL (Jha et al., 2006). 
Modifications of the compounds were done after considering the van de Waals 
interactions between aryl B and a possible complementary area on binding site. All 
synthesized compounds were evaluated initially against M. tuberculosis H37Rv 
(ATCC 27294) using concentration of 12.5 µg/mL and 6.25 µg/mL. The research 
uncovered that the expanding of hydrophilic-hydrophobic methoxy substituent in 
ring B lead to the 1-[4-(2-aminoeth-oxy)phenylcarbonyl]-3,5-bis(benzylidene)-4-
piperidones (3-5) resulted in 98, 99 and 100 % inhibition at 6.25 µg/mL, 
respectively, which shown as a new cluster of anti-mycobacterial (Das et al., 2008).  
 
In 2013, R.S.P Singh and co-workers have prepared almost the same structure 
moieties and screened against the drug-sensitive D6 and the C235 drug-resistant 
strains of Plasmodium falciparum using the SYBR Green-I based fluorescence assay, 
the results showed that the compound (6) demonstrated potent anti-malarial 
properties with IC50 values of 0.60 and 1.97 µM against the drug sensitive D6 strain 
and the C235 drug-resistant strain of Plasmodium falciparum. This compound 
concentrates in red blood cells, permeates across CACO-2 cells and lowers 
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glutathione concentrations in erythrocytes. These data revealed compound 6 to be a 
promising lead compound in the search for novel anti-malarial agents (R. S. P. Singh 
et al., 2013). 
 
Makarov (2009) observed that some representative of 3,5-bis(benzylidene)-
piperidine-4-one derivatives from the previous research (Szakács et al., 2004) 
demonstrate fluorescence properties. In the case of cytotoxic material, natural 
fluorescence could be very helpful in tracking targeted organelle in the cell. 
Cytotoxicity activity increase with the increases of electron withdrawing properties 
of the phenyl ring substituents of piperidones and their derivatives. Combination of 
fluorescent and anti-tumor activity properties makes these types of compounds 
attractive candidates for drugs. In this research, they have developed effective 
synthetic approaches to ω-aminophosphonates bearing  piperidone and differing in 
alkylene chain length. Cytotoxic properties studies revealed that a number of 
phosphonates in the 3,5-bis(benzylidene)piperidin-4-ones  series 7 have IC50 values 
in the low micromolecular range towards four human carcinoma cell lines. Thus, it 
concludes that the cytotoxicity increases with the increase of electron withdrawing 
properties of the substituted R and donor amino groups result in increased 
fluorescence emission (Makarov et al., 2009).  
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Most recently, Potter and co-workers (2015) was actively working on design and 
develop a fatty acid conjugated of the established pharmacophore 3,5-
bis(benzylidene)-4-piperidone as the therapeutic agents. All the synthesized 
compounds were evaluated for cytostatic against murine L1210 leukemia cells while 
selected compounds from cytostatic result were investigated for their topoisomeras 
IIα inhibitory activity. The study indicated that N-subtituted 3,5-bis(benzylidene)-4-
piperidone 8 emerged as one of the most potent catalytic inhibitor of topoisomerase 
IIα in vitro. This research shows that the compound was effectively non-toxic anti-
cancer with strong anti-oxidant ability which may act as an auxiliary therapy in 
cancer (Potter et al., 2015). 
 
 2.2 Method of the synthesis of piperidone 
 
Several methods were reported in the literature for introducing varies ring and group 
in the core structure of 3,5-bis(benzylidene)piperidin-4-one. J.R. Dimmock and co-
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workers were the first synthetic chemist to prepare 3,5-bis(benzylidene)piperidin-4-
one for the past years since 1990 by Claisen-Schmidt condensation of 4-piperidone 
of hydrochloric with a series of aromatic aldehyde 10(a-g) in the presence of HCl in 
acetic acid. Then, the study proceed to the acylation of 3,5-
bis(benzylidene)piperidin-4-one 11(a-g) with acryloyl chloride (12) in the presence 
of potassium carbonate furnished 1-acryloyl-3,5-bis(benzylidene)piperidin-4-one 
13(a-g) (Scheme 2.1). This method involves simple work-up and usually the result is 
a single product (Dimmock et al., 2001). 
 
 
Scheme 2.1: The synthesis of derivatives of 1-acryloyl-3,5-bis(benzylidene)-4-
piperidone 13(a-g). 
Makarov (2009) has introduced two possible routes to afford N-(ω-phosphorylalkyl)-
3,5-bis(benzylidene)-piperidin-4-one 16(a-f). The first path was alkylation of parent 
NH-3,5-bis(benzylidene)-piperidin-4-one (14) by phosphorylated halogen (15) as 
outline in Scheme 2.2. 
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Scheme 2.2: Synthetic approach to N-phosphorylalkylated 3,5-bis(benzylidene)-4-
piperidone. 
Aza Michael reaction was also used as another route to synthesis of β-
aminophosphonates bearing the piperidone (17), then condensation of  
phosphorylated piperidone with substituted benzaldehydes under either base or acid 
condition affording the target N-phosphorylalkyl substituted 3,5-
bis(benzylidene)piperidin-4-one 16(a-f)  (Scheme 2.3) (Makarov et al., 2009). 
 
Scheme 2.3: Synthesis of phosphonates. 
A base catalysed condensation reaction of two mol equivalents of 3,5-
bis(benzylidene)-4-piperidones (11a) with one mol equivalent of 1,3-
dibromopropane (20) heated at reflux temperature for 6-7 hours was used to 
synthesize the dimer (21) as depicted in Scheme 2.4 (S. Das et al., 2013). 
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Scheme 2.4: Synthesis of the dimer (21) by base catalysed condensation. 
Recently, Potter and co-workers (2015) employed one-pot synthesis by adding the 
prepared acid chloride dropwise into the mixture of appropriate 3,5-
bis(benzylidene)piperidin-4-one and triethyl amine. The reaction was stirred at room 
temperature overnight as illustrated in Scheme 2.5. 
 
Scheme 2.5: Synthetic strategy to synthesize 3,5-bis(benzylidene)piperidin-4-one 
fatty acid amides. 
In the present study, the synthesis of N-subtituted-3,5-bis(benzylidene)piperidin-4-
one with the phenacyl bromide was followed the methodology used in Scheme 2.1. 
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 2.3 Docking for drugs discovery 
 
Dengue virus is belongs to the family Flaviviridae and is a vital emerging pathogen 
in the development of vaccines and antiviral therapy. Tomlinson and co-workers 
(2009) identified the novel dengue virus (Type 2) protease inhibitors by targeting 
NS3 viral protease that required for virus replication. While other researchers have 
identified protease inhibitors either using high-throughput screening (HTS) method 
or using bioassays method by identifying the compounds that mimic the peptide 
substrate (Leung et al., 2001; Yin et al., 2006a,b). In the first method, they used 
virtual screening to predict which chemical compounds are commercially available 
in the library that could inhibit the dengue virus protease by using two previously 
reported dengue virus type 2 (DENV2) protease crystal structure, the NS3 protease 
domain alone,  PDB (ID: 1BEF) (H. M. K. Murthy, Clum, and Padmanabhan, 1999) 
and the NS3 protease domain complex with the Mung-Bean Bowman-Birk inhibitor, 
PDB (ID: 1DF9) (K. Murthy et al., 2000). The EUDOC program performed the 
virtual screening and the compound having lowest energy score was then tested for 
solubility and protease inhibition activity. In vitro assays resulted in this study 
indicated more than half of the tested compounds showed reduced in vitro NS2B-
NS3 activity (Figure 2.1). This strategy gives a logical progression for early stage 
drug discovery that can be used to successfully identify a potential candidate for 
antiviral drugs (Tomlinson et al., 2009). 
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Figure 2.1: EUDOC-predicted models of bound conformations of compounds that 
demonstrated dengue antiviral activity in cell culture. (A) ARDP0006, EC50 = 
4.2±1.9 and (B) ARDP0009, EC50 =35±8.0 were predicted to interact with active site 
(pink) and P1 pocket (green) residues of the DEN2V protease. Picture was generated 
from (Tomlinson et al., 2009). 
 
In another study, a group of researcher has explored the structure-based molecular 
docking of cyclic peptide as dengue virus inhibitor. Tambunan and co-workers  
(2010) found that disulphide cyclic peptide could be a potential inhibitor against 
NS2B-NS3 complex to inhibit DENV infection. In their research, seven 
cyclopentapeptide inhibitors involving S-S disulfide bridge designed against DENV2 
NS2B-NS3 protease. All peptide were then analyzed for its enzyme-inhibitor binding 
interaction by docking study. The enzyme structure used in this study was available 
in the protein data bank (PDB) (ID: 2FOM). The docking was performed using 
AutoDock 4.0 software which was reported to be the most popular docking program 
(Hetényi and van der Spoel, 2002) . The seven cyclopentapeptides proposed are 
suitable for design of drug because of their high activity and specificity despite the 
low solubility. The proposed cyclopentapeptide structures exhibited as the promising 
peptide inhibitor with lowest free energy binding of -8.39 kcal/mol and small 
inhibition constant, Ki of 0.71 µM. It indicated that the ligands were favorable 
towards binding site compared to the standard inhibitor (Ki=5.80 µM) (Figure 2.2) 
(Tambunan and Alamudi 2010).  
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Figure 2.2: View of ligand conformation at the binding site. (a) Standard ligand, (b) 
cyclopeptide ligand. Contact residues of the enzyme that interact with the ligands are 
shown as grey sticks. Catalytic triads are shown as balls and sticks. Picture was 
generated from (Tambunan and Alamudi, 2010). 
 
Continuation from their previous study, a cyclic peptide with a positively charged 
amino acid was designed as DENV NS2B-NS3 protease, using computational 
docking techniques. The protein structure was retrieved from PDB (ID: 2FOM) and 
the peptide were docked using MOE (Molecular Operating Environment) software 
package. The study reported that peptide (Cys-NRK-Cys) was successfully blocked 
NS2B-NS3 protease and may serve as an important drug candidate while, peptides 
(Cys-RKG-Cys), (Cys-KRR-Cys), and (Cys-GNRK-Cys) had potential interaction 
with the active site (Idrees and Ashfaq, 2014) (Table 2.1). Thus, the study concluded 
that these peptides could serve as important inhibitors to inhibit the viral replication 
and need further in vitro investigation to confirm their efficiency. 
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Peptide  S score RMSD 
Interacting Residue 
(Hydrogen 
bonding) 
Close contact 
residue 
Cys-RKG-Cys -10.10698 3.335608 Arg54, Asp75, 
Glu101, Ser135, 
Asn152, Gly153 
Trp50. His51, 
Leu128, Pro132, 
Tyr150       
Cys-NRK-Cys -11.12951 2.531304 His51, Asp75, 
Glu101, Asp129, 
Phe130, Ser135, 
Tyr150, Asn152, 
Gly153, Tyr161 
Leu128, Pro132 
      
Cys-RGK-Cys -7.159595 2.026983 Phe130, Asn152, 
Gly153 
His51, Asp75, 
Leu128, Pro132, 
Ser135, Tyr150, 
Gly151       
Cys-KRR-Cys -8.459515 2.113997 Trp50, Ser135, 
Gly151, Gly153 
His51, Arg54, 
Asp75, Tyr150, 
Asn152, Tyr161       
Cys-GRKR-Cys -8.357669 2.004721 Leu128, Phe130, 
Gly153 
His51, Ser127, 
Asp129, Ser131, 
Pro132, Ser135, 
Tyr150, Gly151, 
Tyr161       
Cys-GNRK-Cys -7.681766 1.846913 Phe130, Ser135, 
Gly151, Asn152, 
Gly153 
His51, Asp75, 
Leu128, Pro132, 
Tyr150, Tyr161       
Cys-KKRR-Cys -8.353346 2.254074 Arg54, Leu128, 
Phe130, Asn152, 
Gly153 
His51, Pro132, 
Ser135, Gly151, 
Val154, Tyr161       
 
Table 2.1: Peptide interaction with DENV NS2B-NS3. Table was adapted from  
(Idrees and Ashfaq, 2014) 
 
Most recent study by Yotmanee (2015) revealed that previous crystal structure of 
DENV2 NS3 using PDB (ID: 1BEF) and (ID: 1DF9) cannot confirm the analysis of 
the interaction between potential inhibitor and the complete NS2B-NS3 protein due 
to the missing cofactor NS2B in these crystal structures. Although the crystal 
structure of the DENV2 NS2B-NS3 complex (ID: 2FOM) was available, the 
information on the substrate/inhibitor binding was not inferable (Yotmanee et al., 
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2015). Thus, homology modeling for DENV2 was prepared by Wichapong and co-
workers (2010) due to the lacking of 3D structure of the inhibitor-bound form of 
DENV NS2B-NS3 protease. It was built based on the available data that 
recommended that the West Nile Virus (WNV) protease should be close to the active 
inhibitor complex form of DENV2 NS2B/NS3 protease. The X-ray structure of the 
related WNV NS2B-NS3 protease complexed with the peptidic inhibitor benzoyl-
norleucine (P4)-lysine (P3)-arginine (P2)-arginine (P1)-aldehyde (Bz-Nle-Arg-Arg-
H) (2FP7) was recently published (Figure 2.3) (Wichapong et al., 2010) 
  
Figure 2.3: (A) Interaction of the tetrapeptidic inhibitor with the WNV NS2B-NS3 
protease (taken from the crystal 2FP7). (B) Schematic representation of the 
interaction of the inhibitor with the substrate pocket of WNV NS2B-NS3 protease. 
Diagram was generated from (Wichapong et al., 2010). 
 
Thus, the researchers introduced the DENV protease homology models and WNV 
protease crystal structure by superimposing them on their backbone atom of NS2B-
NS3 protease (Figure 2.4). The analysis revealed that the homology model proposed 
by Wichapong showed high structural similarity as indicated by low RMSD value 
(0.06 Å). This model is the first completed structure of the protease including the 
complete cofactor NS2B in the productive form, thus it could be applied for target-
based design and screening of small molecule inhibitors (Wichapong et al., 2010).  
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Figure 2.4: Superimposition of WNV and DENV. The individual structure is colored 
as follows; WNV and 2FP7: NS2B blue, NS3 red, inhibitor cyan; DV-2: NS2B 
orange, NS3 gray, inhibitor magenta. Picture was generated from (Wichapong et al., 
2010). 
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CHAPTER 3 
MATERIALS AND METHODS 
 
 
3.1 Chemicals and Materials 
 
3.1.1 Chemicals and Solvents 
 
The chemicals and solvents used in the synthesis and characterization of the 
synthesized compounds are as follows: 2-Bromo-4’-methoxyacetophenone 97% 
(Sigma-Aldrich,USA), 2-Bromo-4’-floroacetophenone 97% (Sigma-Aldrich,USA), 
Potassium Carbonate (Merck, Germany), Magnesium sulphate anhydrous (Merck, 
Germany); Acetone, AR grade (QReC); Chloroform, AR grade (QReC); 
Dichloromethane, AR grade (QReC); Diethyl ether, AR grade (QReC); Ethanol, AR 
Grade (QReC); Ethyl-acetate, AR Grade(QReC); Dimethylsulfoxide-d6-deuteration 
degree for NMR (Merck, Germany); Chloroform-D1-deuteration degree for NMR 
spectroscopy (Merck, Germany); Methanol, AR grade (QReC); n-hexane, AR grade 
(QReC); Petroleum ether AR grade (QReC); Potassium bromide, FT-IR grade 
(Sigma-Aldrich,USA). All chemicals and solvents were of reagent grade and were 
used without further purification. 
3.1.2 Materials 
 
The following are the list of materials used for the extraction, separation and 
purification of all synthesized compounds; TLC Silica gel 60 F254, aluminiums 
sheets, 20 cm x 20 cm (Merck, Germany), and Silica gel 60, for column 
chromatography, (0.040-0.063 mm), (230-400 mesh ASTM) (Merck, Germany). 
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3.2 Characterization of Compounds 
 
All the synthesized compounds were characterized by their melting points and 
different spectroscopic techniques; Infrared (IR), 1D and 2D Nuclear Magnetic 
Resonance (NMR) spectroscopy, elemental analysis and X-Ray Crystallography 
analysis was performed when applicable. 
 3.2.1 Melting point 
 
The melting point of all synthesized compounds were measured using open capillary 
tubes by Stuart Scientific SMPI melting point apparatus in the temperature ranging 
from 25 to 350 
o
C at the School of Chemical Sciences, USM. 
 3.2.2 Infrared (IR) Spectroscopy 
 
The Fourier transform infrared (FT-IR) spectra were recorded on a Perkin-Elmer 
2000 FT-IR at the School of Chemical Sciences, USM. All samples were prepared as 
potassium bromide (KBr) disc and analyzed in the range of 4000-650 cm
-1
. FT-IR is 
a simple and rapid analysis that can be used to identify the functional groups of the 
compounds. 
3.2.3 Nuclear Magnetic Resonance (NMR) Spectroscopy  
 
The 1D (
1
H, 
13
C) and 2D (
1
H-
1
H-COSY, HSQC and HMBC) NMR spectra were 
recorded by Bruker (Avance) 500 MHz NMR instrument using TMS as an internal 
standard at School of Chemical Sciences, USM. Standard Bruker software was used 
throughout for plotting. The samples were prepared by dissolving the solid sample 
(~20.00 mg) into the solvent (2 mL) using either deuterated dimethylsulfoxide 
(DMSO-d6) or deuterated chloroform (CDCl3-d1) which was then transferred into an 
22 
 
NMR tube and analyzed using the instrument. Chemical shift is given in parts per 
million (δ- scale) and the coupling constants are given in Hertz (Hz). The spectrum 
data is usually plotted in graph of intensity versus frequency. 
3.2.4 CHN Elemental analysis 
 
CHN analysis is the analytical technique to estimate the percentage of each element 
of carbon (C), hydrogen (H) and nitrogen (N) in a compound. Elemental analysis was 
performed on a Perkin Elmer 2400 Series II, Elemental CHN analyzer at School of 
Chemical Sciences, USM and the experimental values were within ± 0.4% of the 
theoretical values. 
3.3 General Procedure for the synthesis of 3,5-bis((E)-benzylidene)-1-(2-(4-
methoxyphenyl)-2-oxoethyl) piperidin-4-one and its derivatives. 26(a-j) 
 
A mixture of the starting materials, 3,5-bis((E)-benzylidene)piperidin-4-one 11(a-j) 
(0.73 mmol) and K2CO3 (1.45 mmol) was stirred in ethanol (10 mL) at room 
temperature. A 2-bromo-4-methoxy-acetophenone (24) (1.45 mmol) was added 
dropwise to the mixture while stirring. The ethanol is used as reaction medium 
instead of methanol due to its solubility with the starting materials. The reaction 
mixture was left overnight, resulting in the formation of a yellow colored solid. After 
completion of the reaction as evident by TLC of ethylacetate:petroleum ether with 
ratio 2:8, the reaction mixture was poured into the ice, the precipitate formed, filtered 
and washed with water to afford 26(a-j). The steps to synthesize all the targeted 
compounds are shown in the Scheme 3.1. (Dimmock et al., 2001) 
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Scheme 3.1 : Steps to synthesize piperidone derivatives 26(a-j). 
 
3.3.1 Synthesis of 3,5-bis((E)-benzylidene)-1-(2-(4-methoxyphenyl)-2-oxoethyl) 
piperidin-4-one (26a) 
 
Yellow solid, (0.27 g, 87.38 %), mp 115-117 
o
C, IR KBr (cm
-1
): 2941 (Csp
2
H), 1682 
(C=O), 1602 (C=C), 1175 (C-N); Anal. Calcd. For C28H25NO3: C, 79.41; H, 5.95; N, 
3.31, Found: C, 78.83; H, 5.59; N, 3.09. 
1
H NMR (500 MHz, CDCl3): δ 3.84 (3H, s, 
H-15), 4.00 (2H, s, H-7) , 4.10 (4H, s, H-2, H-6), 6.87 (2H, d, H-11, H-13, J=8.50 
Hz), 7.39-7.40 (10H, m, H-2’, H-3’, H-4’, H-5’, H-6’), 7.90 (2H, d, H-10, H-14, 
J=9.00 Hz). 
13
C NMR (125 MHz, CDCl3): δ 54.55 (C-2, C-6), 55.48 (C-15), 62.32 
(C-7), 113.75 (C-11, C-13), 128.62 (C-4’), 128.73 (C-9), 129.06 (C-2’, C-6’), 130.43 
(C-3’, C-5’), 130.46 (C-14, C-10), 132.98 (C-1’), 135.14 (C-5, C-3), 136.81 (C-
arylidene), 163.73 (C-12), 187.26 (C-4), 195.01 (C-8). 
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3.3.2 1-(2-(4-methoxyphenyl)-2-oxoethyl)-3,5-bis((E)-2-methylbenzylidene) 
piperidin-4-one (26b) 
 
Orange solid, (0.21 g, 70.50 %), mp 118-120 
o
C, IR KBr (cm
-1
): 2931 (Csp
2
H), 1673 
(C=O), 1597 (C=C), 1257 (C-N); Anal. Calcd. For C30H29NO3: C, 79.80; H, 6.47; N, 
3.10, Found: C, 79.55; H, 6.44; N, 2.89. 
1
H NMR (500 MHz, CDCl3): δ 2.35 (6H, s, 
H-7’), 3.84 (3H, s, H-15) 3.91 (4H, s, H-2, H-6), 3.92 (2H, s, H-7), 6.86 (2H, d, H-13, 
H-11, J=8.50 Hz), 7.22-7.27 (8H, m, H-3’, H-4’, H-5’, H-6’), 7.84 (2H, d, H-14, H-
10, J=9.00 Hz), 8.00 (2H, s, H-arylidene). 
13
C NMR (125 MHz, CDCl3): δ 20.04 (C-
7’), 54.42 (C-2, C-6), 55.46 (C-15), 62.28 (C-7), 113.69 (C-11, C-13), 125.63 (C-5’), 
128.76 (C-9), 128.87 (C-6’), 128.91 (C-3’), 130.31 (C-4’), 130.35 (C-10, C-14), 
133.12 (C-2’), 134.19 (C-1’), 136.28 (C-arylidene), 138.16 (C-3, C-5), 163.64 (C-12), 
194.88 (C-4), 207.02 (C-8). 
3.3.3 1-(2(-4-methoxyphenyl)-2-oxoethyl)-3,5-bis((E)-4-methylbenzylidene) 
piperidin-4-one(26c) 
 
Yellow solid, (0.20 g, 67.10 %), mp 130-132 
o
C, IR KBr (cm
-1
): 2966 (Csp
2
H), 1688 
(C=O), 1605 (C=C), 1190 (C-N); Anal. Calcd. For C30H29NO3: C, 79.80; H, 6.47; N, 
3.10, Found: C, 79.60; H, 6.43; N, 2.95. 
1
H NMR (500 MHz, CDCl3): δ 2.37 (6H, s, 
H-7’), 3.83 (3H, s, H-15), 3.99 (2H, s, H-7), 4.09 (4H, s, H-2, H-6), 6.86 (2H, d, H-
11, H-13, J=9.00 Hz), 7.20 (4H, d, H-3’, H-5’, J=8.00 Hz), 7.30 (4H, t, H-2’, H-6’, 
J=8.00 Hz), 7.81 (2H, s, H-arylidene), 7.91 (2H, d, H-10, H-14, J=9.00 Hz). 
13
C 
NMR (125 MHz, CDCl3): δ 21.42 (C-7’), 54.66 (C-2, C-6), 55.46 (C-15), 62.37 (C-
7), 113.72 (C-11, C-13), 128.76 (C-9), 129.37 (C-2’, C-6’), 130.49 (C-3’, C-5’), 
130.55 (C-10, C-14), 132.22 (C-1’), 132.37 (C-4’), 136.80 (C-arylidene), 139.40 (C-
3, C-5), 163.70 (C-12), 195.03 (C-4), 207.01 (C-8).  
